The Presence of Serum p53 Antibody Predicts the Pathological Tumor Response to Neoadjuvant Chemotherapy with Docetaxel, Cisplatin and Fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma

@article{Hiyoshi2016ThePO,
  title={The Presence of Serum p53 Antibody Predicts the Pathological Tumor Response to Neoadjuvant Chemotherapy with Docetaxel, Cisplatin and Fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma},
  author={Yukiharu Hiyoshi and Naoya Yoshida and Masayuki Watanabe and Junji Kurashige and Yoshifumi Baba and Yasuo Sakamoto and Hideo Baba},
  journal={World Journal of Surgery},
  year={2016},
  volume={41},
  pages={480-486}
}
Docetaxel, cisplatin and fluorouracil (DCF) is a candidate neoadjuvant chemotherapy (NAC) regimen for esophageal squamous cell carcinoma (ESCC). Although the efficacy and safety of DCF have been reported, the markers that predict the patient’s response are still unknown. The aim of this study was to identify the predictive markers for a response to NAC with DCF in patients with ESCC. A total of 79 patients who received preoperative DCF followed by esophagectomy between August 2008 and December… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

References

Publications referenced by this paper.
Showing 1-10 of 43 references

Similar Papers

Loading similar papers…